Background: Intra-abdominal abscesses [IAAs] are common life-threatening complications in patients with Crohn's disease [CD]. In addition to interventional drainage and surgical therapy, empirical antibiotic therapy represents a cornerstone of treatment, but contemporary data on microbial spectra and antimicrobial resistance are scarce. Methods: We recruited 105 patients with CD and IAAs from nine German centres for a prospective registry in order to characterize the microbiological spectrum, resistance profiles, antibiotic therapy and outcome. Resistance to third-generation cephalosporins, penicillins with beta-lactamase inhibitors and quinolones were observed in 51, 36 and 35 patients, respectively. Seven patients had multiple-drug-resistant bacteria.
Introduction
Intra-abdominal abscesses [IAAs] are frequent, potentially life-threatening complications in patients with Crohn's disease [CD] , occurring in up to 18% of patients. 1, 2 Therapeutic strategies comprise the use of antibiotics, interventional drainage and surgery. Owing to a lack of prospective studies, current treatment concepts are based on retrospective data and case series, and favour a combination of antibiotic therapy and percutaneous drainage, followed by delayed surgical therapy if necessary. [3] [4] [5] [6] [7] [8] Known risk factors for the failure of non-surgical therapeutic concepts are abscess size, ongoing immunosuppression or steroid medication and fistulating disease. [2] [3] [4] 9 For intra-abdominal infections [IAI] , the selection of empirical antibiotic therapy should be based on local epidemiology, individual patient risk factors for difficult-to-treat pathogens, and the clinical severity of infection. 10 Comparable with patients without CD, 11,12 the major pathogens causing IAAs are autochthonous colonic flora and comprise E. coli, Streptococcus spp., Enterococcus spp. and anaerobes as major identified organisms. 2, 13 However, recent studies also show an alarming increase in quinolone-resistant E. coli, 13 intrinsic 3GC-resistant Enterococcus faecium 14 and Candida spp. 15 in CD patients at risk from centres in Asia and North America. As prospective data on the microbiological spectrum and antibiotic resistance for Germany are missing, we implemented a prospective multicenter registry in order to characterize the microbial spectrum, antibiotic resistance and risk factors for therapy failure in CD patients with IAAs.
Methods

Study design
To characterize the pathogen spectrum and resistance patterns, patients with CD, who underwent microbiological sampling of IAAs were prospectively included from nine German university and nonuniversity centres between March 2013 and July 2016. Pus from IAAs was obtained either by percutaneous puncture guided by ultrasound or computed tomography [CT] or during surgical procedures. Microbial cultures were obtained, processed and analysed according to local standard procedures. Data were prospectively collected using an electronic CRF system [OpenClinica] . The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the internal review board [local ethics committee; 3783-05/13].
Definition of multiple-drug resistance
Gram-negative bacteria were defined as multidrug-resistant if they were non-susceptible to at least one agent in at least three antimicrobial categories [MDR] and non-susceptible to at least 1 agent in all but two or fewer categories [XDR] 
Statistical analysis
Statistical analyses were performed using SPSS 20 [IBM Inc., Armonk, New York, USA]. Statistical differences were performed using the non-parametric Mann-Whitney U test, Kruskal-Wallis test for comparison of continuous data, or Fisher's exact test for discrete variables, as appropriate. The significance level in two-sided testing was p < 0.05 without correction for multiple testing. Data are given as absolute number and percentage or as median with first and third quartiles.
Results
A total of 105 consecutive patients with IAAs due to CD were prospectively studied between March 2013 and July 2016. Patients had a median age of 32 years and presented with a median disease history of CD of 6 years [range: 0 to 49 years]. Thirty-six per cent of patients had isolated ileal disease, 26% had colonic disease and 36% had ileocolonic disease, and 40 [38%] patients had undergone previous CD-related surgery [ Ongoing antibiotic therapy before microbiological sampling was not associated with higher rates of antibiotic resistance to the three antibiotic classes [ Table 3 ]. Indicators of resistance against quinolones and broad-spectrum penicillins were higher white blood cell count, whereas resistance against 3GCs was more often observed in patients with lower C-reactive protein levels [ Table 3 ]. Patients with microorganisms resistant to 3GCs more often had colonic or ileocolonic in contrast to ileal manifestation [ In 53 patients, isolated pathogens were fully susceptible to empirical antibiotic therapy, whereas antimicrobial resistance to empirical therapy was observed in 30 patients. Antibiotic regimens associated with non-susceptible pathogens were penicillin-based in 14 patients, 3GC-based regimens in 9 patients, quinolone-based in 6 patients, and monotherapy with linezolid in one patient. Administration of antibiotics before microbiological sampling showed a trend towards, but was not significantly associated with, sterile culture results [p = 0.081]. Fungi were not more frequently isolated in patients receiving antibiotics before sampling [16.4% vs 10.0%, p = 1.000] Culture findings of microorganisms with antimicrobial resistance leading to change in empirically chosen antibiotic treatment 
Discussion
Current epidemiological data on IAAs in CD are mostly based on small cases series or retrospective monocentric data, 2,13,15 and data from large prospective studies are missing. In this German prospective multicenter registry of CD patients with IAAs, we report a high rate of inadequate antimicrobial empirical first-line therapy based on obtained antimicrobial resistance profiles. Inadequate therapy was more often observed in patients receiving immunosuppressive therapy and was associated with longer hospital stay, indicating clinical relevance. It is important to note that in this cohort, in which the vast majority of patients were treated with immunosuppressants, we could not find an increased overall risk of MDR in patients treated with steroids, thiopurines or anti-TNF. Only elevated white blood cell count was associated an increased probability for quinolone or penicillin/BLI resistance. Colonic or ileocolonic disease was associated with an increased probability for 3GC-resistant pathogens.
Due to lack of robust data on microbiological patterns in abscesses in Crohn's disease, antibiotics are often selected on the basis of data on microbiological patterns in other IAI. However, there can be relevant differences in microbial spectrum in IAI based on the underlying disease. In the current study, the most frequent pathogens was E. coli, followed by Streptococcus spp. In contrast, in Reuken et al., the most frequent pathogens isolated from primary peritonitis in patients with liver cirrhosis were Enterococci, 17 requiring a different antibiotic therapy. Another retrospective study described Candida spp. in 51.9% of all IAI in intensive care patients, 18 whereas it was only isolated in 13.2% of the patients in the current study.
The lack of robust microbiological data on pathogens in CD-associated IAAs resulted in a broad variety of antibiotic regimens in our study. Overall, 20 different antibiotic combinations were used. Antibiotic resistance is an emerging problem also in IAI, 19, 20 and ciprofloxacin resistance in up to two-thirds of gram-negative isolates in patients with Crohn's diseases in a retrospective study from Korea. 13 Inadequate empirical therapy was associated with a longer hospital stay [21 vs 13 days], which is in line with reported outcomes for IAI from our group 21 and others, [22] [23] [24] [25] and which translates into increased mortality and costs. 17, [24] [25] [26] The association of white blood cell count with resistance to quinolones and broad-spectrum penicillins with BLI may help to improve future antibiotic regimens. However, there are many potential confounders of this association, underlining the need for prospective evaluation. Especially, immunosuppressive medication with prednisolone is known to elevate white blood cell count and was used frequently in patients included in the current register. Surgical or interventional procedures are other potential confounders. Compared with high rates of antibiotic resistance in other recent studies from Asia and North America, empirical therapy rates of MDR pathogens were rather low in our register, with only 4 MDR Enterobacteriacae.
14,27 Antibiotic resistance was predominantly associated with the following factors. Quinolone-resistance is an increasing problem in CD patients with IAI. In our study, quinolone-resistant Enterobacteriacae were isolated in 12 patients. Recent studies reported quinoloneresistance in up to two-thirds of gram-negative isolates 13 in CD patients, and other studies reported high rates of quinolone resistance in IAI. 11, [28] [29] [30] Increasing rates of resistance are challenging the use of quinolones as first-line therapy in IAI in patients at risk, such as those with nosocomial acquisition, with previous quinolone therapy, or under steroid therapy 10 ; these categories of patients were also identified in our study as being at risk of quinolone-resistant E. coli infections.
(ii) The second factor associated with high rates of antibiotic resistance is the frequent isolation of pathogens, which are per se resistant against one class of antibiotics, such as enterococci against cephalosporins or fungi against antibiotics. Recent studies found high rates of enterococcal-associated IAI 11, 17 that were associated with an increase in mortality in patients suffering from acute pancreatitis 31 or spontaneous bacterial peritonitis. 17 Our study could not identify risk factors for infection with Enterococcus spp. in CD patients, but resistance against 3GCs was associated with colonic localization of the CD and lower CRP levels. Other risk factors associated with intra-abdominal enterococcal infections are a history of antibiotic therapy, 17 nosocomial acquisition and immunosuppression. 17, 32, 33 The second pathogen accounting for a high rate of non-susceptible therapy is Candida spp., which was isolated in 13 patients in our study [12.4%] . Other studies reported Candida in up to 28.9% of IAI in intensive care units, 34 with higher rates occurring when the origin of the intra-abdominal infection is in the upper-gastrointestinal tract due to normal colonization. 10, 35 Intra-abdominal Candida infection is associated with a poor prognosis in patients with nosocomial acquisition 36 and mortality can reach up to 48% in these patients. Other risk factors associated with mortality in Candida infection are high APACHE II Score, respiratory failure or origin of the infection from the upper gastrointestinal tract. 37 Delayed antifungal therapy is known to be associated with an increase in mortality. 38, 39 Contrasting these facts, the calculated antifungal therapy was zero percent in our registry, despite the isolation of Candida spp. in 12.4% of the 105 patients included. Therefore, antifungal therapy has to be taken into account when choosing antimicrobial therapy in CD patients with IAAs.
Current therapeutic concepts for the management of IAA in CD consist of the combination of antibiotic therapy and interventional or percutaneous drainage followed by surgical therapy if necessary. [3] [4] [5] [6] [7] [8] The optimum time-point for delayed surgery still has to be defined. Some authors suggest 6-8 weeks, 40 whereas others recommend only 2-3 weeks. 41 Percutaneous drainage can avoid surgical therapy in up to 30% of patients, 3, 42 and a small study could not find differences in primary outcome when comparing patients undergoing surgical therapy with those receiving antibiotic therapy only, 15 but patients receiving antibiotic therapy alone had a high recurrence rate of 29%. A recent meta-analysis did not find significant differences between percutaneous and surgical drainage with respect to length of hospital stay, stoma requirement or post-procedural complications. 42 Contrasting that, inadequate antibiotic therapy pre-operative is associated with an increased risk of septic complications (occurring in up to 30% of these patients) and an increased number of patients requiring a stoma. 43 In order to optimize therapeutic concepts dealing with antibiotic therapy alone without surgical therapy and for the pre-operative management of CD patients with IAAs, knowledge of the antibiotic-resistance pattern is crucial for therapeutic success; therefore, microbiological sampling should be performed in order to detect resistant pathogens and to optimize antibiotic therapy.
To our knowledge, this is the first prospective, multicentre register evaluating microbiological patterns and resistances in patients suffering from CD in Germany, and may therefore serve as a basis for optimizing antibiotic regimens in selection of antibiotic substances. Quinolones should not be used in patients treated with steroids or when local resistance data indicates high rates of quinolone-resistant Enterococci.
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